118 related articles for article (PubMed ID: 18471157)
21. High-dose caspofungin as a component of combination antifungal therapy in 91 patients with neoplastic diseases and hematopoietic stem cell transplantation: a critical review of short-term and long-term adverse events.
Safdar A; Rodriguez G; Zuniga J; Al Akhrass F; Pande A
J Pharm Pract; 2015 Apr; 28(2):175-82. PubMed ID: 24366977
[TBL] [Abstract][Full Text] [Related]
22. A retrospective analysis of the use of caspofungin in recipients of liver transplant with a modified high index of suspicion for fungal infection. A critical review of mortality, acute cellular rejection, infections, and changes in the liver function tests while on caspofungin.
Doria C; Bodzin AS; Vaccino S; Daskalakis C; Krawitz S; Ramirez CB
Clin Transplant; 2011; 25(4):569-75. PubMed ID: 20662881
[TBL] [Abstract][Full Text] [Related]
23. Caspofungin versus micafungin in the incidence of hepatotoxicity in patients with normal to moderate liver failure.
Shibata Y; Hagihara M; Kato H; Kawasumi N; Hirai J; Nishiyama N; Asai N; Koizumi Y; Yamagishi Y; Matsuura K; Mikamo H
J Infect Chemother; 2017 Jun; 23(6):349-353. PubMed ID: 28431933
[TBL] [Abstract][Full Text] [Related]
24. Safety of the concomitant use of caspofungin and cyclosporin A in patients with invasive fungal infections.
Sanz-Rodriguez C; Lopez-Duarte M; Jurado M; Lopez J; Arranz R; Cisneros JM; Martino ML; Garcia-Sanchez PJ; Morales P; Olivé T; Rovira M; Solano C
Bone Marrow Transplant; 2004 Jul; 34(1):13-20. PubMed ID: 15122312
[TBL] [Abstract][Full Text] [Related]
25. Caspofungin for invasive fungal infections: combination treatment with liposomal amphotericin B in children undergoing hemopoietic stem cell transplantation.
Pancham S; Hemmaway C; New H; Albert E; Dokal I; Roberts IA; McCloy M
Pediatr Transplant; 2005 Apr; 9(2):254-7. PubMed ID: 15787803
[TBL] [Abstract][Full Text] [Related]
26. Safety and Efficacy of Intermittent Intravenous Administration of High-Dose Micafungin.
Neofytos D; Huang YT; Cheng K; Cohen N; Perales MA; Barker J; Giralt S; Jakubowski A; Papanicolaou G
Clin Infect Dis; 2015 Dec; 61 Suppl 6(Suppl 6):S652-61. PubMed ID: 26567284
[TBL] [Abstract][Full Text] [Related]
27. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study.
Herbrecht R; Maertens J; Baila L; Aoun M; Heinz W; Martino R; Schwartz S; Ullmann AJ; Meert L; Paesmans M; Marchetti O; Akan H; Ameye L; Shivaprakash M; Viscoli C
Bone Marrow Transplant; 2010 Jul; 45(7):1227-33. PubMed ID: 20062093
[TBL] [Abstract][Full Text] [Related]
28. A clinical cohort trial of antifungal combination therapy: efficacy and toxicity in haematological cancer patients.
Rieger CT; Ostermann H; Kolb HJ; Fiegl M; Huppmann S; Morgenstern N; Tischer J
Ann Hematol; 2008 Nov; 87(11):915-22. PubMed ID: 18641986
[TBL] [Abstract][Full Text] [Related]
29. Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation.
Trenschel R; Ditschkowski M; Elmaagacli AH; Koldehoff M; Ottinger H; Steckel N; Hlinka M; Peceny R; Rath PM; Dermoumi H; Beelen DW
Bone Marrow Transplant; 2005 Mar; 35(6):583-6. PubMed ID: 15756283
[TBL] [Abstract][Full Text] [Related]
30. Switching to anidulafungin from caspofungin in cancer patients in the setting of liver dysfunction is associated with improvement of liver function tests.
Jung DS; Tverdek FP; Jiang Y; Kontoyiannis DP
J Antimicrob Chemother; 2015 Nov; 70(11):3100-6. PubMed ID: 26311837
[TBL] [Abstract][Full Text] [Related]
31. Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin.
Madureira A; Bergeron A; Lacroix C; Robin M; Rocha V; de Latour RP; Ferry C; Devergie A; Lapalu J; Gluckmana E; Socié G; Ghannoum M; Ribaud P
Int J Antimicrob Agents; 2007 Dec; 30(6):551-4. PubMed ID: 18029149
[TBL] [Abstract][Full Text] [Related]
32. Voriconazole and sirolimus coadministration after allogeneic hematopoietic stem cell transplantation.
Marty FM; Lowry CM; Cutler CS; Campbell BJ; Fiumara K; Baden LR; Antin JH
Biol Blood Marrow Transplant; 2006 May; 12(5):552-9. PubMed ID: 16635790
[TBL] [Abstract][Full Text] [Related]
33. Caspofungin: a major breakthrough in treatment of systemic fungal infections.
Agarwal MB; Rathi SA; Ratho N; Subramanian R
J Assoc Physicians India; 2006 Dec; 54():943-8. PubMed ID: 17334012
[TBL] [Abstract][Full Text] [Related]
34. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
[TBL] [Abstract][Full Text] [Related]
35. Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants.
Migoya EM; Mistry GC; Stone JA; Comisar W; Sun P; Norcross A; Bi S; Winchell GA; Ghosh K; Uemera N; Deutsch PJ; Wagner JA
J Clin Pharmacol; 2011 Feb; 51(2):202-11. PubMed ID: 20679501
[TBL] [Abstract][Full Text] [Related]
36. Impact of risk stratification on the duration of caspofungin therapy for invasive fungal disease in acute leukemic patients.
Li W; Zhao X; Gong B; Liu Y; Wei S; Zhang G; Liu K; Liu B; Wei H; Wang Y; Lin D; Mi Y; Wang J
Future Microbiol; 2015; 10(2):161-8. PubMed ID: 25689528
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of caspofungin in ICU patients.
Muilwijk EW; Schouten JA; van Leeuwen HJ; van Zanten AR; de Lange DW; Colbers A; Verweij PE; Burger DM; Pickkers P; Brüggemann RJ
J Antimicrob Chemother; 2014 Dec; 69(12):3294-9. PubMed ID: 25139840
[TBL] [Abstract][Full Text] [Related]
38. Safety experience with caspofungin in pediatric patients.
Zaoutis T; Lehrnbecher T; Groll AH; Steinbach WJ; Jafri HS; Maertens J; Ngai AL; Chow JW; Taylor AF; Strohmaier KM; Bourque M; Bradshaw SK; Petrecz M; Kartsonis NA
Pediatr Infect Dis J; 2009 Dec; 28(12):1132-5. PubMed ID: 19779392
[TBL] [Abstract][Full Text] [Related]
39. [Pharmacokinetics and pharmacodynamics: interactions and adverse effects. Comparison with other echinocandins].
Azanza JR; Montejo M
Enferm Infecc Microbiol Clin; 2008 Dec; 26 Suppl 14():14-20. PubMed ID: 19572430
[TBL] [Abstract][Full Text] [Related]
40. Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients.
Fortún J; Martín-Dávila P; Montejo M; Muñoz P; Cisneros JM; Ramos A; Aragón C; Blanes M; San Juan R; Gavaldá J; Llinares P;
Transplantation; 2009 Feb; 87(3):424-35. PubMed ID: 19202450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
